Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome
Reata Pharmaceuticals, Inc. - Class A (RETA)
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.reatapharma.com
Company Research
Source: GlobeNewswire
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT ACHIEVED KEY SECONDARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN RETAINED EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT AND WITHDRAWAL OF DRUG FOR 4 WEEKS CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR NOVEMBER 12, 2019 AT 8:00 AM ET PLANO, Texas, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, announced today that the Phase 3 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) caused by Alport syndrome met its primary and key secondary endpoints. After 48 weeks of treatment, patients treated with bardoxolone had a statistically significant improvement compared to placebo in mean estimated glomerular filtration rate (eGFR) of 9.50 mL/min/1.73 m2 (p2 (p=0.0012). Bardoxolone treatment
Show less
Read more
Impact Snapshot
Event Time:
RETA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RETA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RETA alerts
High impacting Reata Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics